Loading insider details...
Beta
Latest Form 4 (Sep 19, 2026): Grant/Award of 5,054 ROIV shares.
Every alert includes an AI-written analysis of the filing, plus news and market context.
| Filed | Company | Transaction | Shares | Value |
|---|---|---|---|---|
| Sep 19, 2026 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 5,054 | n/a |
| Jul 1, 2026 | Roivant Sciences Ltd. (ROIV) | Sale | 300,783 | $10.20M |
| Feb 14, 2026 | Roivant Sciences Ltd. (ROIV) | Sale | 425,000 | $11.33M |
| Dec 19, 2025 | Roivant Sciences Ltd. (ROIV) | Sale | 275,000 | $6.31M |
| Nov 22, 2025 | Roivant Sciences Ltd. (ROIV) | Sale | 850,000 | $17.21M |
| Sep 13, 2025 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 14,524 | n/a |
| Jun 27, 2025 | Roivant Sciences Ltd. (ROIV) | Other (see footnotes) | 6,205,368 | n/a |
| Sep 27, 2024 | Roivant Sciences Ltd. (ROIV) | Sale | 368,052 | $4.28M |
| Sep 13, 2024 | Roivant Sciences Ltd. (ROIV) | Grant/Award | 16,406 | n/a |
| Aug 16, 2024 | Arbutus Biopharma Corp (ABUS) | Exercise/Conversion | 54,915 | $30.8K |